Clin Mol Hepatol.  2013 Mar;19(1):70-77. 10.3350/cmh.2013.19.1.70.

Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE

• Jun CH
• Ki HS
• Lee KH
• Park KJ
• Park SY
• Cho SB
• Park CH
• Joo YE
• Kim HS
• Choi SK
• Rew JS

• KMID: 1493577
• DOI: http://doi.org/10.3350/cmh.2013.19.1.70

Abstract

BACKGROUND/AIMS
The aim of this study was to determine the relationship between serum CRP levels and the prognosis of hepatocellular carcinoma (HCC) patients.
METHODS
HCC patients who underwent the first session of transcatheter arterial chemoembolization (TACE) between January 2005 and December 2009 (n=211) were analyzed retrospectively. The patients were divided into two groups: high C-reactive protein (CRP; > or =1 mg/dL, n=51) and low CRP (<1 mg/dL, n=160). They were followed for a mean of 22.44 months and their clinicoradiological variables and overall survival were compared.
RESULTS
There were significant differences between the two groups in regard to tumor type, tumor-progression-free survival, 10-month mortality, white blood cell (WBC) count, tumor size, and TNM stage. Multivariate analysis revealed that a high serum CRP level was independently associated with tumor size and tumor type. Subgroup analysis of CRP groups according to tumor size demonstrated that a high serum level of CRP was significantly associated with poorly defined (diffuse) tumor type in the tumor size <5 cm group [hazard ratio (HR)=4.81, P=0.018]. A Lipiodol dose exceeding 7 mL (HR=5.55, P=0.046) and the 10-month mortality (HR=7.693, P=0.004) were significantly associated with high serum CRP level in the group of patients with a tumor size of > or =5 cm. In addition, subgroup analysis of matched CRP according to TNM stage revealed that elevated serum CRP was independently associated with tumor type, WBC count, and tumorprogression-free survival.
CONCLUSIONS
A high serum CRP level is associated with large tumors and a poorly defined tumor type, and is significantly associated with 10-month mortality in patients with large HCC (size > or =5 cm) who undergo TACE.

Keyword

C-reactive protein; Chemoembolization; Hepatocellular carcinoma; Prognosis; Progression-free survival

MeSH Terms

Adult
Aged
Aged, 80 and over
C-Reactive Protein/*analysis
Carcinoma, Hepatocellular/metabolism/mortality/*therapy
Chemoembolization, Therapeutic
Disease-Free Survival
Female
Humans
Leukocyte Count
Liver Neoplasms/metabolism/mortality/*therapy
Male
Middle Aged
Multivariate Analysis
Neoplasm Staging
Prognosis
Proportional Hazards Models
Retrospective Studies
Risk Factors
Severity of Illness Index
C-Reactive Protein